Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
CONTEXT Active surveillance (AS) is an important strategy to reduce prostate cancer overtreatment. However, the optimal criteria for eligibility and predictors of progression while on AS are debated. OBJECTIVE To review primary data on markers, genetic factors and risk stratification for patient selection and predictors of progression during AS. EVIDENCE ACQUISITION Electronic searches were conducted in PubMed, Embase and CENTRAL from inception to April 2014 for original articles on biomarkers and risk stratification for AS. EVIDENCE SYNTHESIS Patient factors associated with AS outcomes in some studies include age, race, and family history. Multiple studies provide consistent evidence that lower percent free PSA, higher Prostate Health Index (phi), higher PSA density and greater biopsy core involvement at baseline predict a greater risk of progression. During follow-up, serial measurements of phi, PSA density, and repeat biopsy results predict later biopsy progression. While some studies have suggested a univariate relationship between urinary PCA3 and TMPRSS2:ERG with adverse biopsy features, these markers have not been consistently shown to independently predict AS outcomes. At this point, there is no conclusive data to support the use of genetic tests in AS Limitations of these studies include heterogeneous definitions of progression and limited follow-up. CONCLUSIONS There is a growing body of literature on patient characteristics, biopsy features, and biomarkers with potential utility in AS. More data are needed on practical applications such as combining these tests into multivariable clinical algorithms and long term outcomes, to further improve AS in the future. PATIENT SUMMARY Several PSA-based tests (free PSA, Prostate Health Index, PSA density) and the extent of cancer on biopsy can help to stratify the risk of progression during AS. Investigation into several other markers is underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521 · cited 1×
“Prostate cancer (PCa) affects many men worldwide, with an estimated 899 000 diagnoses and 258 000 deaths in 2008 [1].”
Prostate-Cancer Mortality at 11 Years of Follow-up
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,245 · cited 1×
“Randomized trials have shown a positive effect of screening, with reductions in disease-specific mortality of up to 21–30% [2,3].”
BackgroundSelf-citationKlotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., & Loblaw, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2180 · Cited by 1,074 · cited 3×
“Some studies showed a significant relationship between agewith PSA evolution, biopsy reclassification, disease progression, and risk of all-cause versus PCa mortality [12,13,17,19–23].”
BackgroundActive surveillance for the management of prostate cancer in a contemporary cohort
Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., et al. (2008) · Cancer · doi:10.1002/cncr.23502 · Cited by 404 · cited 3×
“Dall’Era et al [15] reported that a PSAD >0.15 ng/ml/cc at diagnosis and increasing GS on repeat biopsy were significantly associated with receipt of secondary treatment.”
BackgroundInfluentialSoloway, M. S., Soloway, C. T., Eldefrawy, A., Acosta, K., Kava, B., & Manoharan, M. (2010) · European Urology · doi:10.1016/j.eururo.2010.08.027 · Cited by 272 · cited 1×
“Other studies reported a positive confirmatory biopsy as a risk factor for subsequent progression [48,51], while negative confirmatory biopsy is a favorable prognostic factor [26].”
Backgroundvan As, N. J., Norman, A. R., Thomas, K., Khoo, V. S., Thompson, A., Huddart, R. A., Horwich, A., Dearnaley, D. P., & Parker, C. C. (2008) · European Urology · doi:10.1016/j.eururo.2008.02.039 · Cited by 216 · cited 2×
“Several other studies found no significance between the extent of cancer on biopsy and disease progression or the probability of remaining on AS [11,24,26,28,30,34,42,44,45,48,49].”
BackgroundChanges in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance
Porten, S. P., Whitson, J. M., Cowan, J. E., Cooperberg, M. R., Shinohara, K., Perez, N., Greene, K. L., Meng, M. V., & Carroll, P. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0134 · Cited by 200 · cited 1×
“However, early upgrading on repeat biopsy could imply initial sampling error (reclassification), whereas later upgrading may better reflect tumor dedifferentiation [68].”
BackgroundAli, K., Gunnar, A., Jan‐Erik, D., Lilja, H. G., Pär, L., & Jonas, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22161 · Cited by 157 · cited 1×
“Khatami et al [60] evaluated the role of PSADT as a tool for selecting patients for AS.”
MethodLin, D. W., Newcomb, L. F., Brown, E. C., Brooks, J. D., Carroll, P. R., Feng, Z., Gleave, M. E., Lance, R. S., Sanda, M. G., Thompson, I. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3283 · Cited by 139 · cited 4×
“Two urine markers that have recently been examined are prostate cancer antigen 3 (PCA3) and transmembrane protease, serine 2–v-ets avian erythroblastosis virus E26 oncogene homolog gene fusions (TMPRSS2:ERG) [18,33,66].”
BackgroundResultInfluentialProstate cancer overdiagnosis and overtreatment
Klotz, L. H. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328360332a · Cited by 130 · cited 2×
“Active surveillance (AS) is an important solution to reduce overtreatment [4].”
Background
Cited by
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression
Papachristodoulou, A., Heidegger, I., Virk, R. K., Di Bernardo, M., Kim, J. Y., Laplaca, C., Picech, F., Schäfer, G., De Castro, G. J., Hibshoosh, H., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.07.016 · Cited by 18
Metadata
- Authors
- Loeb, S., Bruinsma, S. M., Nicholson, J., Briganti, A., Pickles, T., Kakehi, Y., Carlsson, S. V., & Roobol, M. J.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 67
- Issue
- 4
- Pages
- 619-626
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2059619755
- Cited by
- 166
- References
- 25
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification. https://app.cochat.ai/papers/10.1016/j.eururo.2014.10.010
- The paper
- Loeb, S., Bruinsma, S. M., Nicholson, J., Briganti, A., Pickles, T., Kakehi, Y., Carlsson, S. V., & Roobol, M. J. (2015). Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification. European Urology. https://doi.org/10.1016/j.eururo.2014.10.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.